First Time Loading...

Zoetis Inc
NYSE:ZTS

Watchlist Manager
Zoetis Inc Logo
Zoetis Inc
NYSE:ZTS
Watchlist
Price: 159.7 USD 0.81% Market Closed
Updated: Apr 30, 2024
ZTS
/
Income Statement
/
Revenue

Zoetis Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Zoetis Inc
Revenue Peer Comparison

Comparables:
JNJ
BMY
PFE
MRK
LLY

Competitive Revenue Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Zoetis Inc
NYSE:ZTS
Revenue
$8.5B
CAGR 3-Years
9%
CAGR 5-Years
8%
CAGR 10-Years
6%
Johnson & Johnson
NYSE:JNJ
Revenue
$81.8B
CAGR 3-Years
-1%
CAGR 5-Years
0%
CAGR 10-Years
1%
Bristol-Myers Squibb Co
NYSE:BMY
Revenue
$45B
CAGR 3-Years
2%
CAGR 5-Years
15%
CAGR 10-Years
11%
Pfizer Inc
NYSE:PFE
Revenue
$58.5B
CAGR 3-Years
12%
CAGR 5-Years
7%
CAGR 10-Years
1%
Merck & Co Inc
NYSE:MRK
Revenue
$60.1B
CAGR 3-Years
13%
CAGR 5-Years
7%
CAGR 10-Years
3%
Eli Lilly and Co
NYSE:LLY
Revenue
$34.1B
CAGR 3-Years
12%
CAGR 5-Years
10%
CAGR 10-Years
4%

Zoetis Inc
Revenue Breakdown

Breakdown by Geography
Zoetis Inc

Total Revenue: 8.5B USD
100%
Total Geographical Area: 8.5B USD
99.1%
United States: 4.6B USD
53.3%
Other Emerging Markets: 784m USD
9.2%
Other Developed Markets: 512m USD
6%
Brazil: 393m USD
4.6%
Australia: 323m USD
3.8%
China: 320m USD
3.7%
United Kingdom: 277m USD
3.2%
Canada: 255m USD
3%
Germany: 202m USD
2.4%
Mexico: 162m USD
1.9%
Japan: 158m USD
1.8%
France: 142m USD
1.7%
Chile: 140m USD
1.6%
Spain: 122m USD
1.4%
Italy: 121m USD
1.4%
Show More
Show Less

Breakdown by Segments
Zoetis Inc

Total Revenue: 8.5B USD
100%
Total Products And Services: 8.5B USD
99.1%
Companion Animal: 5.6B USD
65.3%
Horses: 5.3B USD
61.9%
Livestock: 2.9B USD
33.8%
Parasiticides: 1.9B USD
22.8%
Vaccines: 1.8B USD
20.7%
Cattle: 1.5B USD
17.6%
Dermatology: 1.4B USD
16.7%
Other Pharmaceuticals: 1.3B USD
15%
Anti-Infectives: 1.1B USD
12.4%
Swine: 543m USD
6.4%
Poultry: 524m USD
6.1%
Animal Health Diagnostics: 376m USD
4.4%
Medicated Feed Additives: 354m USD
4.1%
Dogs And Cats: 285m USD
3.3%
Other Non-Pharmaceuticals: 254m USD
3%
Fish: 220m USD
2.6%
Other: 100m USD
1.2%
Contract Manufacturing And Human Health Diagn...: 78m USD
0.9%
Show More
Show Less

See Also

What is Zoetis Inc's Revenue?
Revenue
8.5B USD

Based on the financial report for Dec 31, 2023, Zoetis Inc's Revenue amounts to 8.5B USD.

What is Zoetis Inc's Revenue growth rate?
Revenue CAGR 10Y
6%

Over the last year, the Revenue growth was 6%. The average annual Revenue growth rates for Zoetis Inc have been 9% over the past three years , 8% over the past five years , and 6% over the past ten years .

ALPHA SPREAD
Join more than 132,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.